WANBURYNSEWanbury Limited· PharmaceuticalsMediumNeutral
Announced Mon, 4 Aug · 21:54 IST

Wanbury Limited has informed the Exchange regarding Appointment of Mr Chandran Krishnamoorthy as Whole time Director of the company w.e.f. August 04, 2025.

Management Changes View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Wanbury Limited reported strong unaudited Q1 FY26 results (quarter ended June 30, 2025), with revenue from operations rising to Rs 16,318.40 lakhs from Rs 13,110.82 lakhs in the same quarter last year, a growth of about 24.5%. Profit after tax jumped sharply to Rs 1,349.05 lakhs versus just Rs 103.74 lakhs in Q1 FY25, and basic EPS rose to Rs 4.12 from Rs 0.32. The board also approved the re-appointment of Mr. Chandran Krishnamoorthy (DIN: 00005868) as Whole-time Director for a five-year term effective September 18, 2025, subject to shareholder approval; he has been with Wanbury since 2010. Additionally, 91,500 stock options were granted to employees under the Wanbury ESOP 2016 at Rs 10 per option, and three dormant foreign subsidiaries in the Netherlands, China and the UAE/USA were approved for closure since they never commenced operations.

Likely market impact

Sharply higher profitability versus a weak Q1 FY25 base signals improving operational performance, which is positive for shareholders. The re-appointment of an existing leader provides management continuity, while winding up non-operational foreign subsidiaries is a minor housekeeping step with no impact on revenue or earnings.